•  
  •  
 

Document Type

Original Article

Abstract

Background: Major complications of diabetes include diabetic nephropathy (DN), the leading cause of end-stage renal disease (ESRD). When DN is diagnosed and treated early on, its progression to ESRD can be slowed. It is recommended to start screening for DN at the time of diagnosis because approximately three percent of newly diagnosed cases of T2DM already have overt nephropathy. Aim and objectives: to test podocalyxin in the urine for its potential as a non-invasive diagnostic for early diagnosis of diabetic kidney damage. Subjects and methods: Eighty patients were analyzed in this cross-sectional study that took place over the course of six months in the internal medicine and nephrology units at AlAzhar University Hospitals. Results: The variations among the groups were statistically significant with regards to Duration of disease, Random Blood Glucose (mg/dL), Alb/Cr ratio (mg/g), HbA1c (%),urinary-PDX (ng/ml) and Fundus examination. No statistically significant variations were found between the groups. Demographic characteristics, Renal U/S and Pearson’s correlation coefficients (r) between u-PDX and Random Blood Glucose (mg/dL), Alb/Cr ratio (mg/g), HbA1c (%),Serum Total proteins (g/dL), Serum Albumin (g/dL), Blood Urea (mg/dL), Serum Creatinine (mg/dL) and eGFR (ml/ min/ 1.73 m2) among studied groups. Conclusion: These results recommend that u-PDX may play a significant role in the early diagnosis of podocyte damage and DN. There is a high prevalence of u-PDX elevation in T2DM normoalbuminuric people, and u-PDX is more useful in diagnosing DN than microalbumin.

Keywords

Urinary Podocalyxin; Diabetic Kidney Disease; Early Diagnosis.

Subject Area

Internal Medicine

Download

Share

COinS